Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1996 2
1997 2
2001 1
2002 1
2004 2
2006 1
2008 1
2010 1
2011 1
2012 3
2013 2
2014 2
2015 1
2018 2
2019 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation and management of periampullary tumors.
Ross WA, Bismar MM. Ross WA, et al. Curr Gastroenterol Rep. 2004 Oct;6(5):362-70. doi: 10.1007/s11894-004-0051-0. Curr Gastroenterol Rep. 2004. PMID: 15341711 Review.
Periampullary cancers make up 5% of all gastrointestinal cancers. The complexity of the periampullary anatomy makes determination of the origin of some of these tumors difficult. ...However, endoscopic removal is being extended to different lesions with encouraging …
Periampullary cancers make up 5% of all gastrointestinal cancers. The complexity of the periampullary anatomy makes determinat …
Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment.
Erdmann JI, Eskens FA, Vollmer CM, Kok NF, Groot Koerkamp B, Biermann K, van Eijck CH. Erdmann JI, et al. Ann Surg Oncol. 2015 Jul;22(7):2401-7. doi: 10.1245/s10434-014-4267-4. Epub 2014 Dec 12. Ann Surg Oncol. 2015. PMID: 25503345 Review.
The benefit of adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma (PDAC) has been confirmed in randomized controlled trials. For nonpancreatic periampullary cancers (NPPC) originating from the distal bile duct, duodenum, ampulla, or papilla o …
The benefit of adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma (PDAC) has been confirmed in randomized con …
Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study.
de Jong EJM, van der Geest LG, Besselink MG, Bouwense SAW, Buijsen J, Dejong CHC, Koerkamp BG, Heij LR, de Hingh IHJT, Hoge C, Kazemier G, van Laarhoven HWM, de Meijer VE, Stommel MWJ, Tjan-Heijnen VCG, Valkenburg-van Iersel LBJ, Wilmink JW, Geurts SME, de Vos-Geelen J; Dutch Pancreatic Cancer Group. de Jong EJM, et al. HPB (Oxford). 2022 Sep;24(9):1433-1442. doi: 10.1016/j.hpb.2022.01.009. Epub 2022 Jan 23. HPB (Oxford). 2022. PMID: 35135724 Free article.
BACKGROUND: Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC), distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal adenocarcinoma (DA). ...Neoadjuvant and/or adjuvant therapy was administered in 22% of PDA …
BACKGROUND: Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC), distal cholangiocarcinoma (DC), …
Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinoma.
Abrams RA. Abrams RA. Cancer J. 2012 Nov-Dec;18(6):624-32. doi: 10.1097/PPO.0b013e3182758c84. Cancer J. 2012. PMID: 23187851 Review.
Presently, many oncologists feel that radiotherapy should not be part of curative intent, adjuvant management for pancreatic adenocarcinoma ("pancreatic cancer"). Historically, among oncologists who provided adjuvant therapy in this context, radiotherapy was include …
Presently, many oncologists feel that radiotherapy should not be part of curative intent, adjuvant management for pancreatic adenocarcino …
Underutilization of Surgery in Periampullary Cancer Treatment.
Michalski CW, Liu B, Heckler M, Roth S, Sun H, Heger U, Büchler MW, Hackert T. Michalski CW, et al. J Gastrointest Surg. 2019 May;23(5):959-965. doi: 10.1007/s11605-018-3897-4. Epub 2018 Aug 7. J Gastrointest Surg. 2019. PMID: 30088190
BACKGROUND: Site-specific outcomes of resection for periampullary cancer have not been analyzed on a large, registry-based scale. ...Resection was compared to no resection. RESULTS: Resection was the main therapy in stages 1 and 2 (res …
BACKGROUND: Site-specific outcomes of resection for periampullary cancer have not been analyzed on a large, registry-based sca …
Oncologic management of ampullary cancer: International survey among surgical and medical oncologists.
de Jong EJM, Lemmers DHL, Benedetti Cacciaguerra A, Bouwense SAW, Geurts SME, Tjan-Heijnen VCG, Valkenburg-van Iersel LBJ, Wilmink JW, Besselink MG, Abu Hilal M, de Vos-Geelen J. de Jong EJM, et al. Surg Oncol. 2022 Sep;44:101841. doi: 10.1016/j.suronc.2022.101841. Epub 2022 Sep 1. Surg Oncol. 2022. PMID: 36087543 Free article.
BACKGROUND: Ampullary adenocarcinoma (AAC) is a rare neoplasm which as a result is lacking specific treatment guidelines. ...The majority of respondents (87%) stated that the histological AAC subtype (e.g. intestinal vs. pancreatobiliary) was determined in the resection …
BACKGROUND: Ampullary adenocarcinoma (AAC) is a rare neoplasm which as a result is lacking specific treatment guidelines. ...The majo …
Prognostic factors and treatment outcomes in patients with non-ampullary small bowel adenocarcinoma: Long-term analysis.
Tian J, Liu J, Guo C, Yang X, Yang Y, Gou H, Qiu M, Cao D. Tian J, et al. Medicine (Baltimore). 2019 Apr;98(17):e15381. doi: 10.1097/MD.0000000000015381. Medicine (Baltimore). 2019. PMID: 31027129 Free PMC article.
Small bowel adenocarcinoma (SBA) is a relatively rare malignancy in gastrointestinal tumors. ...Intestinal obstruction was the common clinical manifestation at first diagnosis, with a tendency of early peritoneal metastasis. Precaution of the disease in early phase, radica …
Small bowel adenocarcinoma (SBA) is a relatively rare malignancy in gastrointestinal tumors. ...Intestinal obstruction was the common …
Opportunities of improvement in the management of pancreatic and periampullary tumors.
Nordby T, Ikdahl T, Lothe IM, Ånonsen K, Hauge T, Edwin B, Line PD, Labori KJ, Buanes T. Nordby T, et al. Scand J Gastroenterol. 2013 May;48(5):617-25. doi: 10.3109/00365521.2013.781218. Scand J Gastroenterol. 2013. PMID: 23597153 Free PMC article.
Perioperative morbidity rate was 32.6%, mortality 0.7%. Radical resection (R0) was obtained in 23 (41.8%) of 55 patients operated for pancreatic adenocarcinoma and 6.3% underwent reconstructive vascular surgery. Diagnostic failure/delay resulted in unresectable carc …
Perioperative morbidity rate was 32.6%, mortality 0.7%. Radical resection (R0) was obtained in 23 (41.8%) of 55 patients operated for …
Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment.
Poultsides GA, Huang LC, Cameron JL, Tuli R, Lan L, Hruban RH, Pawlik TM, Herman JM, Edil BH, Ahuja N, Choti MA, Wolfgang CL, Schulick RD. Poultsides GA, et al. Ann Surg Oncol. 2012 Jun;19(6):1928-35. doi: 10.1245/s10434-011-2168-3. Epub 2011 Dec 14. Ann Surg Oncol. 2012. PMID: 22167476 Free PMC article.
BACKGROUND: Duodenal adenocarcinoma is a rare cancer usually studied as a group with periampullary or small bowel adenocarcinoma; therefore, its natural history is poorly understood. ...RESULTS: From 1984 to 2006, a total of 122 patients with duodenal aden …
BACKGROUND: Duodenal adenocarcinoma is a rare cancer usually studied as a group with periampullary or small bowel adenocarc …
Surgical management of cholangiocarcinoma.
Jarnagin WR, Shoup M. Jarnagin WR, et al. Semin Liver Dis. 2004 May;24(2):189-99. doi: 10.1055/s-2004-828895. Semin Liver Dis. 2004. PMID: 15192791 Review.
Twenty to 30% of cholangiocarcinomas originate in the lower bile duct, and approximately 10% arise within the intrahepatic biliary tree and will present as an intrahepatic mass. Complete resection remains the most effective and only potentially curative therapy for …
Twenty to 30% of cholangiocarcinomas originate in the lower bile duct, and approximately 10% arise within the intrahepatic biliary tree and …
25 results